Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TIRACAN
2024-512616-21-00Phase 2Authorised
- Sponsor
- University Medical Center Groningen
- Start
- Nov 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of atezolizumab and tiragolumab in head and neck squamous cell carcinoma (HNSCC), Nonhematologic neoplasms, melanoma and 1 more (4 arms), sponsored by University Medical Center Groningen. Primary endpoint: Pathologic response of the primary tumor (pTR) in HNSCC and overall response rate (ORR). Planned start Nov 2024; status: authorised.
02
Drugs
atezolizumabtiragolumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)Nonhematologic neoplasmsmelanomasolid tumor
Beyond the preview
Go deeper on 2024-512616-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512616-21-00.